Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
1. Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of
the allotinib combined mXELIRI protocol.
2. To evaluate the safety and tolerance of the combination of anlotinib and mXELIRI in the
second-line treatment of patients with advanced colorectal cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Guangzhou University of Traditional Chinese Medicine
Collaborator:
Guangdong Provincial Hospital of Traditional Chinese Medicine